Somatostatin analogues and the risk of post-operative pancreatic fistulas after pancreatic resection - A systematic review & meta-analysis

Pancreatology. 2020 Mar;20(2):158-168. doi: 10.1016/j.pan.2019.12.015. Epub 2019 Dec 19.

Abstract

Background: Post-operative pancreatic fistula (POPF) is a common complication of pancreatic resection. Somatostatin analogues (SA) have been used as prophylaxis to reduce its incidence. The aim of this study is to appraise the current literature on the effects of SA prophylaxis on the prevention of POPF following pancreatic resection.

Methods: The review of the literature was conducted using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Data from studies that reported the effects of SA prophylaxis on POPF following pancreatic resection were extracted, to determine the effect of SA on POPF morbidity and mortality.

Results: A total of 15 studies, involving 2221 patients, were included. Meta-analysis revealed significant reductions in overall POPF (Odds ratio: 0.65 (95% CI 0.53-0.81, p < 0.01)), clinically significant POPF (Odds ratio: 0.53 (95% CI 0.34-0.83, p < 0.01)) and overall morbidity (OR: 0.69 (95% CI: 0.50-0.95, p = 0.02)) following SA prophylaxis. There is no evidence that SA prophylaxis reduces mortality (OR: 1.10 (95%CI: 0.68-1.79, p = 0.68)).

Conclusion: SA prophylaxis following pancreatic resection reduces the incidence of POPF. However, mortality is unaffected.

Keywords: Distal pancreatectomy; Octreotide; Pancreatic fistula; Pancreatic resection; Pancreaticoduodenectomy; Pasireotide; Post-operative; Somatostatin analogues; Whipple’s procedure.

Publication types

  • Meta-Analysis
  • Systematic Review

MeSH terms

  • Humans
  • Incidence
  • Pancreas / surgery*
  • Pancreatic Fistula / epidemiology
  • Pancreatic Fistula / etiology
  • Pancreatic Fistula / prevention & control*
  • Postoperative Complications / epidemiology
  • Postoperative Complications / prevention & control*
  • Risk Assessment
  • Somatostatin / analogs & derivatives*
  • Somatostatin / therapeutic use*

Substances

  • Somatostatin